<div><p><b>Background: </b>Patients with primary sclerosing cholangitis (PSC) are at a 400-fold increased risk of cholangiocarcinoma (CCA), and are thus recommended to undergo annual screening with magnetic resonance cholangiopancreatography (MRCP). Unfortunately, MRCP findings are nonspecific for CCA in the setting of biliary fibrosis and screening may not confer a survival benefit. We have previously developed a new class of diagnostic tools that detect dysregulated protease activity in the tumor microenvironment.

<div><p><b>Background: </b>Hepatic encephalopathy (HE) is the most frequent cirrhosis complication leading to hospital admissions and is associated with significant mortality. The aim of this study was to determine the ability of the CyberLiver-Animal Recognition Test (CL-ART) to predict future hospitalisation due to decompensation, especially through HE, comparing its performance to established HE tests.</p>

<div><p><b>Background: </b>Intestine epithelial HIF-1α plays a critical role in the maintaining of gut barrier function. Disrupted gut barrier function contributes to the development of metabolic syndrome. The aim of this study is to determine whether pharmacological or genetic activation of intestinal HIF-1α ameliorates western diet-induced MASLD and metabolic syndrome.</p>

<div><p><b>Background:<span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW146419527 BCX0"> </b><span class="NormalTextRun SCXW146419527 BCX0"> </span><span class="NormalTextRun SCXW146419527 BCX0">Clinician </span><span class="NormalTextRun SCXW146419527 BCX0">inexperience with advanced care planning (ACP) </span><span class="NormalTextRun SCXW146419527 BCX0">is a barrier to patient-centered care for adults </span&

<div><p><b>Background:<span> </b>IL-17 signaling is implicated in the pathogenesis of alcohol-associated liver disease (AALD) leading to steatosis, fibrosis and hepatocellular carcinoma (HCC). We recently demonstrated that the specific deletion of IL-17RA in hepatocytes protects from steatosis, fibrosis and HCC in high fat diet plus ethanol (HFD+EtOH)-fed in MUP uPA mice (model that express urokinase-type plasminogen activator driven by a hepatocyte promoter for major urinary protein).

<div><p><b>Background:</p> </b><p>Primary Sclerosing Cholangitis (PSC) manifests with fibrotic scarring of the intrahepatic and extrahepatic bile ducts due to an immune-mediated inflammatory response. The cyclic GMP–AMP synthase –stimulator of interferon genes (cGAS-STING) signaling pathway is a key mediator of inflammatory gene expression and cytokine release in response to cellular stress. The inflammatory milieu observed in PSC recruits immune cells, including neutrophils, to infiltrate the peri-portal region.

<div><p><strong><b>Background:</strong> </b>Several studies in adults showed that spleen stiffness measurement (SSM) by vibration-controlled transient elastography (VCTE) can accurately assess clinically significant portal hypertension (HTN) and predict presence of esophageal varices. However, pediatric studies on SSM published thus far have used a liver-specific probe to measure the spleen making them difficult to interpret and possibly overestimating SSM, as the spleen is inherently a stiffer organ than the liver.

<div><p><b>Background:<span> </b>Patients with cirrhosis have increased surgical risk compared to the general population. Preoperative optimization by nonsurgical clinicians improves postoperative outcomes after colectomy in studies of patients with major comorbidities, however, data specific to patients with cirrhosis and addressing more diverse surgeries are limited.

<div><p><b>Background: </b>About 30% of patients with PBC have a suboptimal response to ursodeoxycholic acid (UDCA), leading to a worse prognosis. In the phase III POISE trial, response to obeticholic acid (OCA) was assessed by using the POISE score. Recently, complete biochemical normalization (normal ALP and bilirubin ≤ 0.6 ULN) has been proposed as a new therapeutic aim in PBC, as it significantly improves liver-related and overall survival, but the effectiveness of second-line therapy for this new therapeutic target has not been evaluated.</p>

<div><p><b>Background: </b>We reported the HBsAg reduction by a nasal administrative therapeutic vaccine containing HBsAg/HBcAg mixed with mucoadhesive excipient carboxy-vinyl polymer (CVP-NASVAC) in chronically HBV infected patients. This study was aimed to assess the long-term efficacy of CVP-NASVAC at 48 months after the first 10 doses.</p>